Karyopharm Therapeutics Inc. (KPTI) Stock Price & Analysis

Karyopharm Therapeutics Inc. (KPTI) closed at USD 0.88 on Thursday, October 29, 2026, up 5.73% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 0.83; the Oct 29, 2026 session ranged USD 0.78–0.99 on volume of 6,634,785 shares. Market capitalization is $19.96M, with a 52-week range of USD 0.31–10.99 (NMS). Source: Nexqual, retrieved October 29, 2026 at 22:16 UTC.

Also available as compact Markdown for AI agents: nexqual.com/KPTI.md

Key facts (KPTI)

• Last four reported quarters (through Jun 30, 2026): revenue $147M, net income -$225M (-153.3% margin) (SEC filings).
• Insider open-market sales, last ~7 months: 11 Form 4 filings, $42K; 11 not under a Rule 10b5-1 plan ($42K); 0 by opportunistic insiders, 7 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.25 (range 3–11).
• Total return with dividends: 1Y -85.2% vs S&P 500 +14.4%; 5Y -98.9% vs S&P 500 +79.1%.
• Next earnings: 2026-11-03, EPS estimate USD -1.32, revenue estimate $33.5M. All companies reporting that day: https://nexqual.com/earnings/2026-11-03
• Dividend: KPTI paid no cash dividend in the last five years.
• Short interest: 32.20% of float (as of 2026-10-15), 5.2 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (KPTI)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (KPTI)

P/S 0.1x · Earnings yield -1126.23%

Insider sales (SEC Form 4, open-market, last ~7 months) (KPTI)

0 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (KPTI)

Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.25 (low 3, high 11).

Rating changes, last 120 days:

Total return (dividends reinvested) (KPTI)

Dividends (KPTI)

KPTI paid no cash dividend in the last five years.

Short interest (KPTI)

7,266,973 shares sold short, 32.20% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 7,865,168 shares (-7.6%). Days to cover: 5.2 (short shares ÷ average daily volume).

KPTI earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

KPTI recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

KPTI suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 13, 2026.

KPTI company outlook (results filed Aug 13, 2026)

• “Guidance of $130 Million to $150 Million Including U.S.”
• “XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m.”

Quoted word-for-word from the SEC 8-K results press release.

KPTI analyst estimates and revisions

KPTI options: expected move

Options price a move of about ±79.8% (±$0.65) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±7.8% on average.

30-day implied volatility 278.7% vs 269.8% realized over the last 30 trading days. Put/call ratio (volume) 0.63. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 22:16 UTC)

Technical Analysis (KPTI)

Nexqual's technical model rates KPTI "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 22:16 UTC.

Analyst Ratings (KPTI)

Wall Street analysts rate KPTI "Buy" based on 5 analysts, with a mean price target of USD 7.25 (range USD 3–11), per Nexqual as of October 29, 2026 at 22:16 UTC.

Earnings (KPTI)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 22:16 UTC.

Financials & Fundamentals (KPTI)

Source: Nexqual, October 29, 2026 at 22:16 UTC.

Financial Health Score (KPTI)

Nexqual rates Karyopharm Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 22:16 UTC.

Ownership (KPTI)

Source: Nexqual, October 29, 2026 at 22:16 UTC.

Leadership (KPTI)

Karyopharm Therapeutics Inc. is led by Richard A. Paulson, President, CEO & Director, per Nexqual as of October 29, 2026 at 22:16 UTC.

Major Backers & Investors (KPTI)

Notable institutional backers of Karyopharm Therapeutics Inc. include RA Capital Management, L.P., Adage Capital Partners GP L.L.C., Acorn Capital Advisors, LLC , according to Nexqual as of October 29, 2026 at 22:16 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 22:16 UTC.

From Karyopharm Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)

Key Strengths & Strategy (as disclosed to the SEC)

• Our science enables us to potentially make a big difference in the lives of patients.

Partnerships

• In October 2023, we entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company ("BMS") to evaluate mezigdomide, BMS' proprietary investigational cereblon E3 ligase modulator (CELMoD™) agent, in combination with selinexor in patients with relapsed or refractory multiple myeloma progressing after T-cell immunotherapies.
• Further, in connection with the XPORT-EC-042 Trial, we entered into a global collaboration with Foundation Medicine, Inc. to develop FoundationOne®CDx, a tissue-based next generation sequencing test to identify and enroll patients whose tumors are TP53 wild-type.

Legal & Regulatory Risks (Item 1A, quoted)

• We, or our collaborators, may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our or their products in any market.
• We, or our collaborators, may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for our product candidates.
• We may not be able to successfully and timely complete these post-approval requirements, obtain an extension, if needed, or complete any other post-marketing confirmatory study as required to maintain approval or achieve full approval of our products.
• The FDA and comparable foreign regulatory authorities may also impose requirements for costly surveillance to monitor the safety or efficacy of an approved drug.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:16 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt